US Patent

US11793796 — Inhibition of crystal growth of roflumilast

Formulation · Assigned to Arcutis Biotherapeutics Inc · Expires 2037-06-07 · 11y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition that inhibits the growth of roflumilast crystals during storage by including hexylene glycol.

USPTO Abstract

Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.

Drugs covered by this patent

Patent Metadata

Patent number
US11793796
Jurisdiction
US
Classification
Formulation
Expires
2037-06-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Arcutis Biotherapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.